LabGenomics Reports 4.3 Billion KRW Q1 Net Profit... Quarterly Profit Without COVID Kits
LabGenomics announced on the 15th that it recorded sales of 14.7 billion KRW in the first quarter. Operating profit and net profit for the same period were 1.1 billion KRW and 4.3 billion KRW, respectively.
As the spread of COVID-19 decreased, the number of PCR (molecular diagnostic) tests significantly declined, causing most diagnostic kit companies to experience poor performance. However, LabGenomics achieved profitability by securing sales channels through diagnostic services and overseas genetic testing.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- President Lee: "Disability Rights Guarantee Act, the First Step Toward Ensuring Rights, Not Charity"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
LabGenomics has established a solid financial structure through stable sales generated from diagnostic services. Based on this, the company plans to actively expand its gene analysis services based on NGS (next-generation sequencing).
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
